New drug MR13A9 shows promise for Dialysis-Related itching

NCT ID NCT03802617

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tested a drug called MR13A9 in 247 Japanese adults on hemodialysis who had severe itching (uremic pruritus). Participants received either MR13A9 or a placebo intravenously. The goal was to see if the drug reduces itch intensity over 8 weeks. Results could lead to a new treatment for this uncomfortable condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

MR13A9 (a drug given intravenously)

What this could lead to

If successful, this could provide a new treatment option for severe itching in people on dialysis.

What could go wrong

This is a Phase 2 trial, so it is still early. The drug may not prove effective or safe enough for approval. Side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UREMIC PRURITUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    Multiple Locations, Japan